- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
- Interventions
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Huntersville, North Carolina
Condition Directory
Lung Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 18, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
4379
Shown on this page
12
Current sort
Recently updated
Condition scope
Lung Cancer
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Lung Cancer studies are organized in the registry
The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 445–456 of 4,379 matching trials for Lung Cancer.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
- Interventions
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Relapsed/Refractory Small Cell Lung Cancer
- Interventions
- BMS-986525, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Neoplastic Disease, Solid Tumor
- Interventions
- Indocyanine Green
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Iadademstat, Atezolizumab, SBRT
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Interventions
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer, Non-small Cell Lung Cancer
- Interventions
- TUB-040
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 15 more
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Questionnaire Administration, Stereotactic Radiosurgery
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- M1774, Cemiplimab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Pittsburgh, Pennsylvania • Knoxville, Tennessee + 2 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Drug · Other
- Lead sponsor
- Razor Genomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Mission Viejo, California • Sacramento, California • Santa Rosa, California + 15 more
About this Lung Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lung Cancer.